BioSpace News Archive

The FY20 Defense Appropriations Act provides funding to the Department of Defense Peer Reviewed Medical Research Program to support medical research projects of clear scientific merit and direct relevance to military health.

In a painful blow to the San Francisco-based company, the committees voted unanimously, 27 to 0, not to recommend approval.

In 2016, Soon-Shiong announced the Cancer Moonshot and set a 2020 deadline, claiming he would transform the war on cancer.

The Indianapolis-based company announced lower-priced versions of Humalog Mix75/25 KwikPen (insulin lispro protamine and insulin lispro injectable suspension 100 units/mL) and Humalog Junior KwikPen (insulin lispro injection 100 units/mL).

It’s entirely possible that what is now being seen as a digital transformation in so many areas will in time merely become a standard set of tools used in all areas of the life sciences, from drug discovery and development, regulation and actual therapeutic devices.

While the conditions surrounding the City by the Bay are in a negative light, there is still a significant amount of positive news coming out of the conference.

Companies from across the globe provide updates to their business and pipeline.

Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation technologies, announces that it has exercised its option to exclusively license a novel Base Editing technology from Rutgers, The State University of New Jersey, for use in therapeutic, diagnostic and service applications.

Elekta Infinity and Elekta Synergy systems to alleviate China’s burden of cancer

JT and its subsidiary, Torii Pharmaceutical, receive rights to develop and commercialize tapinarof for psoriasis and atopic dermatitis in Japan